可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]卫生部心血管病防治研究中心.中国心血管病报告2008~2009[M].中国大百科全书出版社,2009.
[2]Goldbourt U,Yaari S.Cholesterol and coronary heart disease mortality.A 23-year follow-up study of 9902 men in Israel[J].Arterioscler Thromb Vasc Biol,1990,10(4):512-519.
[3]Roffi M,Patrono C,Collet JP,et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2015,37(3):267-315.
[4]Mackey RH,Greenland P,Goff DC,et al.High-Density Lipoprotein Cholesterol and Particle Concentrations,Carotid Atherosclerosis,and Coronary Events MESA (Multi-Ethnic Study of Atherosclerosis)[J].J Am Coll Cardiol,2012,60(6):508-516.
[5]中国疾病预防控制中心.中国慢性病及其危险因素检测报告2007[M].北京:人民卫生出版社,2010:1-15.
[6]Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease[J].Am J Cardiol,1983,51(3):1.
[7]Takayanagi K,Yamaguchi H,Morooka S,et al.Higher Gensini score of coronary arteries in acute inferior myocardial infarction with precordial ST-segment depression[J].Jpn Heart J,1992,33(1):25-39.
[8]Gordon T,Castelli WP,Hjortland MC,et al.High-density lipoprotein as a protective factor against coronary heart-disease-Framingham study[J].Am J Med,1977,62(5):707-714.
[9]Rader DJ.Illuminating HDL-is it still a viable therapeutic target?[J].New Engl J Med,2007,357(21):2180-2183.
[10]Kastelein JJ,Duivenvoorden R,Deanfield J,et al.Rationale and design of dal-VESSEL:a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation[J].Curr Med Res Opin,2011,27(1):141-150.
[11]Luescher TF,Taddei S,Kaski JC,et al.Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial[J].Eur Heart J,2012,33(7):857-865.
[12]Catalano G,Julia Z,Frisdal E,et al.Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway[J].Arterioscl Throm Vas,2009,29(2):268-275.
[13]钟巧青,赵水平,王 星,等.高密度脂蛋白对3T3-L1脂肪细胞分泌白细胞介素8的影响[J].中华内分泌代谢杂志,2010,26(10):888-890.
[14]钟巧青,赵水平,王 星.高密度脂蛋白对炎症状态下脂肪细胞胆固醇流出的影响[J].中国循环杂志,2012,27(2):145-148.
[15]徐勇霞,傅明德,徐燕华,等.CHD患者冠脉狭窄程度与血清HDL亚类组成的关系[J].四川大学学报(医学版).2004,35(4):500-502.